Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong
· Delayed Price · Currency is HKD 45.60
+0.15 (0.33%)
Jun 6, 2025, 4:08 PM HKT
Shanghai Henlius Biotech Revenue
In the year 2024, Shanghai Henlius Biotech had annual revenue of 5.72B CNY with 6.11% growth. Shanghai Henlius Biotech had revenue of 2.98B in the half year ending December 31, 2024, with 54.69% growth.
Revenue
5.72B CNY
Revenue Growth
+6.11%
P/S Ratio
4.07
Revenue / Employee
1.63M CNY
Employees
3,515
Market Cap
24.78B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.53B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| Innovent Biologics | 10.03B |
| WuXi Biologics | 19.87B |
| CSPC Pharmaceutical Group | 28.99B |
| Sino Biopharmaceutical | 30.72B |
| Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |